Dimethylcelecoxib inhibits prostaglandin E2 production

Biochemical Pharmacology

Volumn 76, Issue 1, 2008, Pages 62-69

  Wobst, Ivonne ^a   Schiffmann, Susanne ^a   Birod, Kerstin ^a   Maier, Thorsten J ^a   Schmidt, Ronald ^a   Angioni, Carlo ^a   Geisslinger, Gerd ^a   Grösch, Sabine ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Cancer; COX; Dimethylcelecoxib; mPGES 1; PGE2

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIMETHYLCELECOXIB; ETORICOXIB; INTERLEUKIN 1BETA; LUMIRACOXIB; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; ROFECOXIB; TUMOR NECROSIS FACTOR ALPHA; VALDECOXIB;

ARTICLE; CANCER CELL CULTURE; CELL CULTURE; CELL FREE SYSTEM; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOSOL; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN CELL; MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

BLOTTING, WESTERN; CELL PROLIFERATION; DINOPROSTONE; HELA CELLS; HUMANS; PROSTAGLANDIN ANTAGONISTS; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES;

EID: 45049086884     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.04.008     Document Type: Article

References (37)

1. Peek Jr. R.M. Prevention of colorectal cancer through the use of COX-2 selective inhibitors. Cancer Chemother Pharmacol 54 Suppl. 1 (2004) S50-S56
2. Rao C.V., and Reddy B.S. NSAIDS and chemoprevention. Curr Cancer Drug Targets 4 1 (2004) 29-42
3. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94 4 (2002) 252-266
4. Evans J.F., and Kargman S.L. Cancer and cyclooxygenase-2 (COX-2) inhibition. Curr Pharm Des 10 6 (2004) 627-634
5. Grosch S., Maier T.J., Schiffmann S., and Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98 11 (2006) 736-747
6. Soh J.W., and Weinstein I.B. Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. Prog Exp Tumor Res 37 (2003) 261-285
7. Tegeder I., Pfeilschifter J., and Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15 12 (2001) 2057-2072
8. Grosch S., Tegeder I., Niederberger E., Brautigam L., and Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15 14 (2001) 2742-2744
9. Grosch S., Tegeder I., Schilling K., Maier T.J., Niederberger E., and Geisslinger G. Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers. FASEB J 17 10 (2003) 1316-1318
10. Janssen A., Maier T.J., Schiffmann S., Coste O., Seegel M., Geisslinger G., et al. Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. Eur J Pharmacol 540 1-3 (2006) 24-33
11. Song X., Lin H.P., Johnson A.J., Tseng P.H., Yang Y.T., Kulp S.K., et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 94 8 (2002) 585-591
12. Penning T.D., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Docter S., et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 40 9 (1997) 1347-1365
13. Schonthal A.H. Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. Neurosurg Focus 20 4 (2006) E21
14. McLemore T.L., Hubbard W.C., Litterst C.L., Liu M.C., Miller S., McMahon N.A., et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res 48 11 (1988) 3140-3147
15. Rigas B., Goldman I.S., and Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122 5 (1993) 518-523
16. Vanderveen E.E., Grekin R.C., Swanson N.A., and Kragballe K. Arachidonic acid metabolites in cutaneous carcinomas. Evidence suggesting that elevated levels of prostaglandins in basal cell carcinomas are associated with an aggressive growth pattern. Arch Dermatol 122 4 (1986) 407-412
17. Jung T.T., Berlinger N.T., and Juhn S.K. Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study. Laryngoscope 95 3 (1985) 307-312
18. Sheng H., Shao J., Morrow J.D., Beauchamp R.D., and DuBois R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58 2 (1998) 362-366
19. Gallo O., Franchi A., Magnelli L., Sardi I., Vannacci A., Boddi V., et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3 1 (2001) 53-61
20. Kamei D., Murakami M., Nakatani Y., Ishikawa Y., Ishii T., and Kudo I. Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem 278 21 (2003) 19396-19405 [Epub March 7, 2003]
21. Brautigam L., Nefflen J.U., and Geisslinger G. Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionization. J Chromatogr B Analyt Technol Biomed Life Sci 788 2 (2003) 309-315
22. Franzen R., Pautz A., Brautigam L., Geisslinger G., Pfeilschifter J., and Huwiler A. Interleukin-1beta induces chronic activation and de Novo synthesis of neutral ceramidase in renal mesangial cells. J Biol Chem 276 38 (2001) 35382-35389
23. Schmidt R., Coste O., and Geisslinger G. LC-MS/MS-analysis of prostaglandin E2 and D2 in microdialysis samples of rats. J Chromatogr B Analyt Technol Biomed Life Sci 826 1/2 (2005) 188-197
24. Thoren S., and Jakobsson P.J. Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4. Eur J Biochem 267 21 (2000) 6428-6434
25. Maier T.J., Schilling K., Schmidt R., Geisslinger G., and Grosch S. Cyclooxygenase (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67 8 (2004) 1469-1478
26. Bage T., Modeer T., Kawakami T., Quezada H.C., and Yucel-Lindberg T. Regulation of prostaglandin E synthases: effects of siRNA-mediated inhibition of microsomal prostaglandin E synthase-1. Biochim Biophys Acta 1773 10 (2007) 1589-1598
27. Mancini J.A., Blood K., Guay J., Gordon R., Claveau D., Chan C.C., et al. Expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. J Biol Chem 276 6 (2001) 4469-4475
28. Schiffmann S, Maier T, Wobst I, Janssen A, Corban-Wilhelm H, et al. The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol, doi:10.1016/j.bcp.2008.04.017.
29. Kardosh A., Wang W., Uddin J., Petasis N.A., Hofman F.M., Chen T.C., et al. Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. Cancer Biol Ther 4 5 (2005) 571-582
30. Lin H.P., Kulp S.K., Tseng P.H., Yang Y.T., Yang C.C., and Chen C.S. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol Cancer Ther 3 12 (2004) 1671-1680
31. Kardosh A., Soriano N., Liu Y.T., Uddin J., Petasis N.A., Hofman F.M., et al. Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood 106 13 (2005) 4330-4338
32. Backhus L.M., Petasis N.A., Uddin J., Schonthal A.H., Bart R.D., Lin Y., et al. Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer. J Thorac Cardiovasc Surg 130 5 (2005) 1406-1412
33. Dempke W., Rie C., Grothey A., and Schmoll H.J. Cyclooxygenase-2: a novel target for cancer chemotherapy?. J Cancer Res Clin Oncol 127 7 (2001) 411-417
34. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30 1 (2000) 3-21
35. Kawamori T., and Wakabayashi K. COX-2 and prostanoid receptors: good targets for chemoprevention. J Environ Pathol Toxicol Oncol 21 2 (2002) 149-153
36. Samuelsson B., Morgenstern R., and Jakobsson P.J. Membrane prostaglandin e synthase-1: a novel therapeutic target. Pharmacol Rev 59 3 (2007) 207-224
37. Riendeau D., Aspiotis R., Ethier D., Gareau Y., Grimm E.L., Guay J., et al. Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg Med Chem Lett 15 14 (2005) 3352-3355